Agenus shared a post on LinkedIn:
“Agenus has published its updated April 2026 corporate overview, highlighting BOT+BAL CRC progress across clinical development, registration momentum, and expansion opportunities.
The deck includes:
- Phase 3 BATTMAN rationale in R/R MSS mCRC
- Durable survival data supporting the program
- Neoadjuvant expansion potential in MSS CRC
- Growing access momentum and commercial readiness
- A stronger financial and manufacturing position
Visit our IR site.
View the deck.”
Other articles from Agenus.